We chose CD22/Siglec-2, Siglec-7, and Siglec-9 as probes, as these Siglecs showed robust binding to B cells from CLL patients in our preliminary experiments (data not shown). Here, CD22 is linked to B-cell chronic lymphocytic leukemia.